KR20150028232A - 프로게스테론 수용체 서브타입의 유방암 예후, 예측 및 유전자 발현을 토대로 한 항프로게스틴 치료에 대한 반응성 예측 방법 - Google Patents
프로게스테론 수용체 서브타입의 유방암 예후, 예측 및 유전자 발현을 토대로 한 항프로게스틴 치료에 대한 반응성 예측 방법 Download PDFInfo
- Publication number
- KR20150028232A KR20150028232A KR20147033298A KR20147033298A KR20150028232A KR 20150028232 A KR20150028232 A KR 20150028232A KR 20147033298 A KR20147033298 A KR 20147033298A KR 20147033298 A KR20147033298 A KR 20147033298A KR 20150028232 A KR20150028232 A KR 20150028232A
- Authority
- KR
- South Korea
- Prior art keywords
- expression
- genes
- cancer
- gene
- progestin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 318
- 238000011282 treatment Methods 0.000 title claims abstract description 141
- 239000003418 antiprogestin Substances 0.000 title claims abstract description 102
- 230000000708 anti-progestin effect Effects 0.000 title claims abstract description 101
- 108090000468 progesterone receptors Proteins 0.000 title claims description 384
- 102000003998 progesterone receptors Human genes 0.000 title claims description 382
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 123
- 206010006187 Breast cancer Diseases 0.000 title claims description 108
- 230000004044 response Effects 0.000 title claims description 24
- 238000004393 prognosis Methods 0.000 title description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 129
- 238000000034 method Methods 0.000 claims abstract description 110
- 201000011510 cancer Diseases 0.000 claims abstract description 70
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 416
- 239000000523 sample Substances 0.000 claims description 67
- 239000000583 progesterone congener Substances 0.000 claims description 63
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 claims description 53
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 claims description 53
- -1 RASCD2 Proteins 0.000 claims description 46
- 239000012472 biological sample Substances 0.000 claims description 43
- 108020004999 messenger RNA Proteins 0.000 claims description 42
- 210000001519 tissue Anatomy 0.000 claims description 41
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 37
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 36
- 101000578830 Homo sapiens Methionine aminopeptidase 1 Proteins 0.000 claims description 29
- 101001057324 Homo sapiens Microtubule-associated protein 1A Proteins 0.000 claims description 29
- 102100028379 Methionine aminopeptidase 1 Human genes 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 24
- 238000002493 microarray Methods 0.000 claims description 24
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims description 23
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims description 23
- 239000013068 control sample Substances 0.000 claims description 23
- 102100024158 Cadherin-10 Human genes 0.000 claims description 20
- 101000762229 Homo sapiens Cadherin-10 Proteins 0.000 claims description 20
- 102100040634 Actin filament-associated protein 1-like 2 Human genes 0.000 claims description 18
- 101000892366 Homo sapiens Actin filament-associated protein 1-like 2 Proteins 0.000 claims description 18
- 101001082864 Homo sapiens Peroxisomal membrane protein 4 Proteins 0.000 claims description 18
- 101000723759 Homo sapiens Zinc finger protein 26 Proteins 0.000 claims description 18
- 102100030555 Peroxisomal membrane protein 4 Human genes 0.000 claims description 18
- 102100028392 Zinc finger protein 26 Human genes 0.000 claims description 18
- 108010061408 Autophagy-Related Protein 12 Proteins 0.000 claims description 17
- 102000012035 Autophagy-Related Protein 12 Human genes 0.000 claims description 17
- 102100035226 GDP-fucose transporter 1 Human genes 0.000 claims description 17
- 101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 claims description 17
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims description 17
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 claims description 17
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 claims description 17
- 101000795338 Homo sapiens Tripartite motif-containing protein 51 Proteins 0.000 claims description 17
- 101000788608 Homo sapiens Tubulin alpha-3D chain Proteins 0.000 claims description 17
- 101000788609 Homo sapiens Tubulin alpha-3E chain Proteins 0.000 claims description 17
- 101000841331 Homo sapiens Urotensin-2B Proteins 0.000 claims description 17
- 102100023428 KH domain-containing, RNA-binding, signal transduction-associated protein 3 Human genes 0.000 claims description 17
- 101710013801 KIAA0513 Proteins 0.000 claims description 17
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims description 17
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 claims description 17
- 108091006955 SLC35C1 Proteins 0.000 claims description 17
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 claims description 17
- 102100029700 Tripartite motif-containing protein 51 Human genes 0.000 claims description 17
- 102100025236 Tubulin alpha-3D chain Human genes 0.000 claims description 17
- 102100025220 Tubulin alpha-3E chain Human genes 0.000 claims description 17
- 102100025702 Uncharacterized protein KIAA0513 Human genes 0.000 claims description 17
- 102100029096 Urotensin-2B Human genes 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102100026096 Claudin-8 Human genes 0.000 claims description 16
- 101000912659 Homo sapiens Claudin-8 Proteins 0.000 claims description 16
- 101000717344 Homo sapiens RNA-binding protein with multiple splicing 2 Proteins 0.000 claims description 16
- 101000707156 Homo sapiens SH2 domain-containing protein 4B Proteins 0.000 claims description 16
- 102100020795 RNA-binding protein with multiple splicing 2 Human genes 0.000 claims description 16
- 102100031769 SH2 domain-containing protein 4B Human genes 0.000 claims description 16
- 239000013074 reference sample Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 8
- 238000010208 microarray analysis Methods 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 238000000636 Northern blotting Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 238000007901 in situ hybridization Methods 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010027191 meningioma Diseases 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 101001047043 Homo sapiens Kelch repeat and BTB domain-containing protein 11 Proteins 0.000 claims description 2
- 102100022827 Kelch repeat and BTB domain-containing protein 11 Human genes 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 53
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 303
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 155
- 108020004414 DNA Proteins 0.000 description 135
- 230000001105 regulatory effect Effects 0.000 description 86
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 85
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 85
- 108091034117 Oligonucleotide Proteins 0.000 description 73
- 230000001419 dependent effect Effects 0.000 description 64
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 52
- 239000002751 oligonucleotide probe Substances 0.000 description 52
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 49
- 238000002474 experimental method Methods 0.000 description 47
- 239000003446 ligand Substances 0.000 description 46
- 239000000186 progesterone Substances 0.000 description 44
- 229960003387 progesterone Drugs 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 239000003623 enhancer Substances 0.000 description 36
- 230000026731 phosphorylation Effects 0.000 description 33
- 238000006366 phosphorylation reaction Methods 0.000 description 33
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 32
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 31
- 230000004547 gene signature Effects 0.000 description 30
- 238000011529 RT qPCR Methods 0.000 description 27
- 230000001939 inductive effect Effects 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 24
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 24
- 102000015694 estrogen receptors Human genes 0.000 description 24
- 108010038795 estrogen receptors Proteins 0.000 description 24
- 230000002103 transcriptional effect Effects 0.000 description 24
- 230000002950 deficient Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000035897 transcription Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 19
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 19
- 102000005969 steroid hormone receptors Human genes 0.000 description 19
- 238000013518 transcription Methods 0.000 description 19
- 230000007246 mechanism Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 108020003113 steroid hormone receptors Proteins 0.000 description 17
- 238000001262 western blot Methods 0.000 description 17
- 108010077544 Chromatin Proteins 0.000 description 16
- 210000003483 chromatin Anatomy 0.000 description 16
- 229960004679 doxorubicin Drugs 0.000 description 16
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 16
- 210000000481 breast Anatomy 0.000 description 15
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 101150038105 pr gene Proteins 0.000 description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 13
- 230000002068 genetic effect Effects 0.000 description 13
- 102000040945 Transcription factor Human genes 0.000 description 12
- 108091023040 Transcription factor Proteins 0.000 description 12
- 230000001195 anabolic effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 10
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 9
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 9
- 108091054455 MAP kinase family Proteins 0.000 description 9
- 102000043136 MAP kinase family Human genes 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 239000003886 aromatase inhibitor Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 238000010195 expression analysis Methods 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 229950011093 onapristone Drugs 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102400001368 Epidermal growth factor Human genes 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 8
- 108010033040 Histones Proteins 0.000 description 8
- 229940116977 epidermal growth factor Drugs 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000003827 upregulation Effects 0.000 description 8
- 108700039887 Essential Genes Proteins 0.000 description 7
- 108010047956 Nucleosomes Proteins 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 229940046836 anti-estrogen Drugs 0.000 description 7
- 230000001833 anti-estrogenic effect Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000000328 estrogen antagonist Substances 0.000 description 7
- 238000010199 gene set enrichment analysis Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000001623 nucleosome Anatomy 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 6
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 229960001603 tamoxifen Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940122815 Aromatase inhibitor Drugs 0.000 description 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 5
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000011223 gene expression profiling Methods 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 5
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- VHZPUDNSVGRVMB-RXDLHWJPSA-N (8s,11r,13s,14s,17s)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(C(=O)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)C(F)(F)C(F)(F)F)[C@]2(C)C1 VHZPUDNSVGRVMB-RXDLHWJPSA-N 0.000 description 4
- CIUICCYYGROKEM-UHFFFAOYSA-N 2h-phenanthren-3-one Chemical compound C1=CC=C2C3=CC(=O)CC=C3C=CC2=C1 CIUICCYYGROKEM-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229960002932 anastrozole Drugs 0.000 description 4
- 229940046844 aromatase inhibitors Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 238000003500 gene array Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229960003881 letrozole Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960003248 mifepristone Drugs 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000008844 regulatory mechanism Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IJLXLZGJDSJGIQ-BILPMHSYSA-N (8r,9s,10r,13s,14s,16r,17s)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@@H](CC)[C@H](C(=O)CO)[C@@]1(C)CC2 IJLXLZGJDSJGIQ-BILPMHSYSA-N 0.000 description 3
- BHERMCLNVOVDPU-DQFOBABISA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(2-methoxyacetyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(O)C(=O)COC)=CC=C(N(C)C)C=C1 BHERMCLNVOVDPU-DQFOBABISA-N 0.000 description 3
- QSFGZNVRVZHUGV-UHFFFAOYSA-N 4-[3-cyclopropyl-5-methyl-1-(methylsulfonylmethyl)pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile Chemical compound C1CC1C1=NN(CS(C)(=O)=O)C(C)=C1OC1=CC(C)=C(C#N)C(C)=C1 QSFGZNVRVZHUGV-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 description 3
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 3
- 101000720379 Homo sapiens Acyl-coenzyme A thioesterase 6 Proteins 0.000 description 3
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 3
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 3
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 3
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 3
- 101710145783 TATA-box-binding protein Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 229960000255 exemestane Drugs 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 208000030776 invasive breast carcinoma Diseases 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229950001947 lonaprisan Drugs 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- 229950005444 telapristone Drugs 0.000 description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 3
- 229960005026 toremifene Drugs 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100025847 Acyl-coenzyme A thioesterase 6 Human genes 0.000 description 2
- RTCKAOKDXNYXEH-FWSJOHTJSA-N Aglepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)\C=C/C)=CC=C(N(C)C)C=C1 RTCKAOKDXNYXEH-FWSJOHTJSA-N 0.000 description 2
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 102100027267 FERM, ARHGEF and pleckstrin domain-containing protein 1 Human genes 0.000 description 2
- 240000008168 Ficus benjamina Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 2
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 101000914701 Homo sapiens FERM, ARHGEF and pleckstrin domain-containing protein 1 Proteins 0.000 description 2
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 2
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 2
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 2
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 2
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
- 101150118523 LYS4 gene Proteins 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 2
- 101150118570 Msx2 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 2
- 101710189720 Porphobilinogen deaminase Proteins 0.000 description 2
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 2
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 229950008045 aglepristone Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229940043275 anti-HER2 drug Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 2
- 229950003620 asoprisnil Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 230000007755 survival signaling Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 101150044870 ACOT6 gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100024439 Adhesion G protein-coupled receptor A2 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 102100039409 Axonemal dynein light intermediate polypeptide 1 Human genes 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 238000007450 ChIP-chip Methods 0.000 description 1
- 238000001353 Chip-sequencing Methods 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 101710161408 Folylpolyglutamate synthase Proteins 0.000 description 1
- 102100035067 Folylpolyglutamate synthase, mitochondrial Human genes 0.000 description 1
- 101710200122 Folylpolyglutamate synthase, mitochondrial Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 101150013707 HBB gene Proteins 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101100107942 Homo sapiens ACOT6 gene Proteins 0.000 description 1
- 101000833358 Homo sapiens Adhesion G protein-coupled receptor A2 Proteins 0.000 description 1
- 101001036313 Homo sapiens Axonemal dynein light intermediate polypeptide 1 Proteins 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 1
- 101000738977 Homo sapiens Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 101000598311 Homo sapiens Serine protease inhibitor Kazal-type 13 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 101150071473 Kr gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101150022373 MAT2A gene Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 101710155795 Probable folylpolyglutamate synthase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101710151871 Putative folylpolyglutamate synthase Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091078180 SR family Proteins 0.000 description 1
- 102100036970 Serine protease inhibitor Kazal-type 13 Human genes 0.000 description 1
- 241001168730 Simo Species 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YJVBLROMQZEFPA-UHFFFAOYSA-L acid red 26 Chemical compound [Na+].[Na+].CC1=CC(C)=CC=C1N=NC1=C(O)C(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=CC=C12 YJVBLROMQZEFPA-UHFFFAOYSA-L 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229950003105 afimoxifene Drugs 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000007476 breast mucinous carcinoma Diseases 0.000 description 1
- 208000024119 breast tumor luminal A or B Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- WUEMPJNONXHVNQ-UHFFFAOYSA-N heptadeca-1,6-dien-5-one Chemical compound C=CCCC(C=CCCCCCCCCCC)=O WUEMPJNONXHVNQ-UHFFFAOYSA-N 0.000 description 1
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000023418 invasive ductal and lobular carcinoma Diseases 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 1
- 229950001701 lilopristone Drugs 0.000 description 1
- 238000011454 long-term hormonal therapy Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- QCDLMPDTVSILSM-UHFFFAOYSA-N n-(3-chloro-4-cyanophenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide Chemical compound FC(F)(F)C(O)(C)C(=O)NC1=CC=C(C#N)C(Cl)=C1 QCDLMPDTVSILSM-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003327 ormeloxifene Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 229960000200 ulipristal Drugs 0.000 description 1
- 229960000499 ulipristal acetate Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639407P | 2012-04-27 | 2012-04-27 | |
| US61/639,407 | 2012-04-27 | ||
| PCT/US2013/032677 WO2013162776A1 (en) | 2012-04-27 | 2013-03-15 | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150028232A true KR20150028232A (ko) | 2015-03-13 |
Family
ID=48045769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20147033298A Withdrawn KR20150028232A (ko) | 2012-04-27 | 2013-03-15 | 프로게스테론 수용체 서브타입의 유방암 예후, 예측 및 유전자 발현을 토대로 한 항프로게스틴 치료에 대한 반응성 예측 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10501800B2 (enExample) |
| EP (1) | EP2841594A1 (enExample) |
| JP (1) | JP2015516155A (enExample) |
| KR (1) | KR20150028232A (enExample) |
| AU (1) | AU2013252913A1 (enExample) |
| CA (1) | CA2871590A1 (enExample) |
| HK (1) | HK1208057A1 (enExample) |
| IL (1) | IL235351A0 (enExample) |
| MX (1) | MX2014013044A (enExample) |
| NZ (1) | NZ701652A (enExample) |
| PH (1) | PH12014502410A1 (enExample) |
| RU (1) | RU2014147625A (enExample) |
| WO (1) | WO2013162776A1 (enExample) |
| ZA (1) | ZA201407853B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501800B2 (en) | 2012-04-27 | 2019-12-10 | Regents Of The University Of Minnesota | Breast cancer prognosis |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140363425A1 (en) * | 2013-03-13 | 2014-12-11 | J. Dinny Graham | Systems and methods for identifying cancers having activated progesterone receptors |
| US20150276767A1 (en) * | 2014-03-12 | 2015-10-01 | The University Of Sydney | Systems and methods for identifying cancers having activated progesterone receptors |
| RU2017112748A (ru) | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| HK1255104A1 (zh) | 2015-12-15 | 2019-08-02 | Context Biopharma Inc. | 无定形的奥那司酮组合物及其制备方法 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| US10942183B2 (en) | 2017-04-05 | 2021-03-09 | Regents Of The University Of Minnesota | Methods of detecting progesterone receptor and of detecting an expression level |
| EP3822368A1 (en) | 2019-11-14 | 2021-05-19 | Koninklijke Philips N.V. | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
| IL296568A (en) * | 2020-03-17 | 2022-11-01 | Regeneron Pharma | Methods and systems for determining responders to treatment |
| JP7619556B2 (ja) * | 2020-10-08 | 2025-01-22 | 藤倉化成株式会社 | 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー |
| US20250005743A1 (en) * | 2023-06-30 | 2025-01-02 | Mackay Memorial Hospital | Method and system for identifying hormone receptor status |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750015B2 (en) * | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| WO2002000618A2 (en) | 2000-06-28 | 2002-01-03 | University Technology Corporation | Progesterone receptor-regulated gene expression and methods related thereto |
| WO2013162776A1 (en) | 2012-04-27 | 2013-10-31 | Lange Carol | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
-
2013
- 2013-03-15 WO PCT/US2013/032677 patent/WO2013162776A1/en not_active Ceased
- 2013-03-15 AU AU2013252913A patent/AU2013252913A1/en not_active Abandoned
- 2013-03-15 RU RU2014147625A patent/RU2014147625A/ru not_active Application Discontinuation
- 2013-03-15 CA CA2871590A patent/CA2871590A1/en not_active Abandoned
- 2013-03-15 EP EP13714144.6A patent/EP2841594A1/en not_active Withdrawn
- 2013-03-15 MX MX2014013044A patent/MX2014013044A/es unknown
- 2013-03-15 HK HK15108666.9A patent/HK1208057A1/xx unknown
- 2013-03-15 US US13/843,482 patent/US10501800B2/en active Active
- 2013-03-15 KR KR20147033298A patent/KR20150028232A/ko not_active Withdrawn
- 2013-03-15 JP JP2015508975A patent/JP2015516155A/ja active Pending
- 2013-03-15 NZ NZ701652A patent/NZ701652A/en not_active IP Right Cessation
-
2014
- 2014-10-27 IL IL235351A patent/IL235351A0/en unknown
- 2014-10-27 PH PH12014502410A patent/PH12014502410A1/en unknown
- 2014-10-28 ZA ZA2014/07853A patent/ZA201407853B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501800B2 (en) | 2012-04-27 | 2019-12-10 | Regents Of The University Of Minnesota | Breast cancer prognosis |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014147625A (ru) | 2016-06-20 |
| HK1208057A1 (en) | 2016-02-19 |
| MX2014013044A (es) | 2015-06-23 |
| NZ701652A (en) | 2016-09-30 |
| US10501800B2 (en) | 2019-12-10 |
| ZA201407853B (en) | 2015-12-23 |
| WO2013162776A1 (en) | 2013-10-31 |
| PH12014502410A1 (en) | 2015-01-12 |
| EP2841594A1 (en) | 2015-03-04 |
| CA2871590A1 (en) | 2013-10-31 |
| JP2015516155A (ja) | 2015-06-11 |
| AU2013252913A1 (en) | 2014-11-27 |
| US20130316992A1 (en) | 2013-11-28 |
| IL235351A0 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10501800B2 (en) | Breast cancer prognosis | |
| Knutson et al. | Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression | |
| JP6381519B2 (ja) | がん転移の予後診断および処置のための方法 | |
| US8877445B2 (en) | Methods for identification of tumor phenotype and treatment | |
| JP6550045B2 (ja) | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 | |
| Zhang et al. | Hypoxia-induced TPM2 methylation is associated with chemoresistance and poor prognosis in breast cancer | |
| Mohebi et al. | Expression analysis of vimentin and the related lncRNA network in breast cancer | |
| Roque et al. | Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project | |
| Stute et al. | Life stage differences in mammary gland gene expression profile in non-human primates | |
| Gu et al. | Targeting thyroid hormone receptor beta in triple-negative breast cancer | |
| Willis et al. | Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs | |
| Wang et al. | EXO1/P53/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression | |
| DeMichele et al. | Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer | |
| Fentiman | The biology of male breast cancer | |
| Siegfried et al. | Expression of PAM50 genes in lung cancer: evidence that interactions between hormone receptors and HER2/HER3 contribute to poor outcome | |
| Milano et al. | What clinicians need to know about antioestrogen resistance in breast cancer therapy | |
| Eissa et al. | Prognostic and biological significance of microRNA-221 in breast cancer | |
| De Mattia et al. | Germline polymorphisms in the nuclear receptors PXR and VDR as novel prognostic markers in metastatic colorectal cancer patients treated with FOLFIRI | |
| Hagiwara et al. | CHFR-promoter-methylation status is predictive of response to irinotecan-based systemic chemotherapy in advanced colorectal cancer | |
| EP2561089A2 (en) | Method of determining the metastatic potential of a tumor | |
| Xiang et al. | Screening for candidate genes related to breast cancer with cDNA microarray analysis | |
| Uysal et al. | Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer | |
| Fuqua | Adrenal tumors in childhood | |
| Ribeiro et al. | Amplification of the insulin-like growth factor 1 receptor gene is a rare event in adrenocortical adenocarcinomas: searching for potential mechanisms of overexpression | |
| Rizzolo et al. | Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20141126 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |